ZEB1 and pancreatic neoplasm: In pancreatic cancer, the application of the HDAC class I inhibitor mocetinostat results in de‐repression of ZEB1‐inhibiting miRNAs, ZEB1 downmodulation, MET, and resensitization to gemcitabine in mice (Meidhof et al, 2015).